MDRNA Gets $1M Milestone as It Ekes Value from Non-RNAi Programs | GenomeWeb

MDRNA announced this week that it has received a $1 million milestone payment from Amylin Pharmaceuticals related to a 2006 deal between the companies to develop a nasal-spray formulation of the diabetes drug exenatide.

According to MDRNA, the payment was made on an accelerated basis after the companies amended their original 2006 agreement. Under the amended arrangement, MDRNA could receive up to $79 million in additional milestones, the company added.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.